cefuroxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 565 55268-75-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefuroxime
  • biofuroxim
  • cefaloxime
  • cefasyn
  • cefuroxim
  • cefuroxime acid
  • cephuroxime
  • cefuroxime sodium
  • cefuroxime sodium salt
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
  • Molecular weight: 424.38
  • Formula: C16H16N4O8S
  • CLOGP: 0.44
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 3
  • TPSA: 173.76
  • ALOGS: -3.17
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O
3 g P
0.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 89 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 96 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 39.35 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67.90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.20 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.830 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.042 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.679 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.281 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 63.260 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 47.930 % High 1
herg hERG pIC50 4.026 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.390 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.793 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 36.310 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 72
kinase-selectivity-class ACVR2A,ACVR2B,AURKB,AURKC,AXL,BMX,BRAF,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FGFR1,GRK2,GSK3B,IRAK1,JAK2,MAP2K3,MAP2K6,MAP3K14,MAP3K2,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,PIM3,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK 36
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.033 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.086 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5 High 1
mppb Mouse plasma protein binding (% unbound) 57.540 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.148 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 44.890 % High 1
rat-kpuu-brain Rat brain Kpuu 0.008 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.884 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.230 % High 1
rppb Rat plasma protein binding (% unbound) 32.370 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 970.510 uM High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 19, 1983 FDA COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 275.68 12.96 143 23138 31474 90573692
Anaphylactic reaction 264.67 12.96 202 23079 87322 90517844
Angioedema 260.81 12.96 178 23103 64698 90540468
Swollen tongue 215.92 12.96 139 23142 45817 90559349
Swelling face 178.88 12.96 156 23125 81196 90523970
Dysphonia 155.09 12.96 129 23152 62955 90542211
Retinal detachment 153.83 12.96 60 23221 6762 90598404
Foetal exposure during pregnancy 145 12.96 106 23175 42869 90562297
Macular oedema 139.01 12.96 51 23230 4858 90600308
Premature baby 135.72 12.96 83 23198 24994 90580172
Drug ineffective for unapproved indication 134.94 12.96 122 23159 66522 90538644
Corneal oedema 106.55 12.96 33 23248 1868 90603298
Drug reaction with eosinophilia and systemic symptoms 104.15 12.96 87 23194 42671 90562495
Bronchospasm 95.64 12.96 62 23219 20647 90584519
Corneal opacity 92.03 12.96 25 23256 886 90604280
Patent ductus arteriosus 88.44 12.96 36 23245 4533 90600633
Joint swelling 84.45 12.96 14 23267 503286 90101880
Type IV hypersensitivity reaction 83.14 12.96 33 23248 3893 90601273
Premature delivery 82.47 12.96 73 23208 38689 90566477
Systemic lupus erythematosus 79.84 12.96 3 23278 361893 90243273
Infusion related reaction 75.99 12.96 9 23272 416771 90188395
Type I hypersensitivity 74.52 12.96 31 23250 4124 90601042
Exposure during pregnancy 73.45 12.96 178 23103 238232 90366934
Retinal oedema 70.22 12.96 21 23260 1055 90604111
Glossodynia 69.85 12.96 3 23278 321776 90283390
Low birth weight baby 68.92 12.96 38 23243 9429 90595737
Cystoid macular oedema 67.64 12.96 24 23257 2076 90603090
Rheumatoid arthritis 65.67 12.96 8 23273 362606 90242560
Anterior chamber inflammation 64.10 12.96 16 23265 404 90604762
Alopecia 63.39 12.96 24 23257 495047 90110119
Pyroglutamic acidosis 62.50 12.96 20 23261 1260 90603906
Rash maculo-papular 62.17 12.96 64 23217 40869 90564297
Endophthalmitis 61.33 12.96 28 23253 4657 90600509
Swelling 59.45 12.96 17 23264 419041 90186125
Circulatory collapse 57.20 12.96 49 23232 24855 90580311
Pericarditis 57.07 12.96 3 23278 270148 90335018
Congenital cytomegalovirus infection 56.94 12.96 12 23269 138 90605028
Pseudomembranous colitis 56.64 12.96 25 23256 3843 90601323
Retinal toxicity 56.45 12.96 19 23262 1403 90603763
Arthropathy 55.49 12.96 13 23268 366229 90238937
Treatment failure 54.30 12.96 7 23274 303921 90301245
Ocular toxicity 53.29 12.96 17 23264 1060 90604106
Retinopathy 52.26 12.96 23 23258 3511 90601655
Foetal anaemia 51.84 12.96 11 23270 131 90605035
Premature rupture of membranes 50.89 12.96 26 23255 5532 90599634
Musculoskeletal stiffness 50.25 12.96 8 23273 296524 90308642
Parophthalmia 49.31 12.96 13 23268 410 90604756
Hypotension 48.20 12.96 188 23093 325209 90279957
Contraindicated product administered 47.25 12.96 12 23269 320127 90285039
Accidental overdose 46.21 12.96 46 23235 28227 90576939
Drug interaction 46.16 12.96 166 23115 276287 90328879
Dysbiosis 45.67 12.96 17 23264 1685 90603481
Vaccination site pain 45.50 12.96 12 23269 379 90604787
Hepatic enzyme increased 45.29 12.96 18 23263 360718 90244448
Clostridium difficile infection 45.08 12.96 51 23230 36194 90568972
Cataract operation complication 44.32 12.96 10 23271 161 90605005
Therapeutic product effect decreased 43.76 12.96 9 23272 277562 90327604
Cross sensitivity reaction 43.56 12.96 19 23262 2838 90602328
Resuscitation 42.46 12.96 15 23266 1281 90603885
Lower respiratory tract infection 41.93 12.96 7 23274 250652 90354514
Deafness congenital 41.61 12.96 9 23272 118 90605048
Pericoronitis 41.34 12.96 9 23272 122 90605044
Corneal deposits 41.07 12.96 11 23270 369 90604797
Intermittent positive pressure breathing 41.03 12.96 8 23273 60 90605106
Wound 39.90 12.96 14 23267 302966 90302200
Hypersensitivity 39.57 12.96 225 23056 454452 90150714
Toxic epidermal necrolysis 39.15 12.96 45 23236 32483 90572683
Psoriatic arthropathy 39.04 12.96 6 23275 228329 90376837
Multiple organ dysfunction syndrome 39.01 12.96 66 23215 68270 90536896
Metabolic acidosis 38.96 12.96 59 23222 55617 90549549
Abdominal discomfort 36.85 12.96 41 23240 477287 90127879
Visual acuity reduced 36.26 12.96 37 23244 23373 90581793
Cardiac arrest 36.25 12.96 82 23199 104853 90500313
Maculopathy 36.06 12.96 16 23265 2490 90602676
Blood pressure decreased 35.89 12.96 67 23214 74828 90530338
Kounis syndrome 35.77 12.96 16 23265 2537 90602629
Clostridium difficile colitis 35.66 12.96 39 23242 26667 90578499
Pain 35.55 12.96 134 23147 996207 89608959
Airway peak pressure increased 35.45 12.96 10 23271 408 90604758
Tachypnoea 35.43 12.96 35 23246 21274 90583892
Congenital tricuspid valve incompetence 34.83 12.96 8 23273 140 90605026
Nasopharyngitis 34.80 12.96 32 23249 407072 90198094
Pneumonia mycoplasmal 34.13 12.96 12 23269 1010 90604156
Meningitis candida 34.10 12.96 7 23274 70 90605096
Ill-defined disorder 33.64 12.96 4 23277 184887 90420279
Trimethylaminuria 32.76 12.96 8 23273 184 90604982
Stevens-Johnson syndrome 32.63 12.96 39 23242 29337 90575829
Foetal non-stress test abnormal 32.23 12.96 6 23275 34 90605132
Tinnitus 32.05 12.96 47 23234 43055 90562111
Cardiovascular insufficiency 32.05 12.96 13 23268 1622 90603544
Lip swelling 31.50 12.96 44 23237 38566 90566600
Periventricular leukomalacia 31.29 12.96 8 23273 223 90604943
Toxic anterior segment syndrome 31.20 12.96 14 23267 2236 90602930
Fatigue 31.15 12.96 172 23109 1153851 89451315
Face oedema 31.04 12.96 34 23247 23284 90581882
Jaundice 31.03 12.96 40 23241 32477 90572689
Toxoplasmosis 30.94 12.96 13 23268 1772 90603394
Conjunctival oedema 30.93 12.96 11 23270 958 90604208
Delivery 30.89 12.96 13 23268 1780 90603386
Congenital pulmonary hypertension 30.40 12.96 7 23274 124 90605042
Renal failure 30.30 12.96 88 23193 130919 90474247
Blood cholesterol increased 30.29 12.96 8 23273 208004 90397162
Cardiac massage 30.22 12.96 5 23276 12 90605154
Product monitoring error 29.71 12.96 17 23264 4527 90600639
Arthralgia 28.85 12.96 103 23178 778419 89826747
Oliguria 28.76 12.96 23 23258 10601 90594565
Intentional product use issue 28.58 12.96 10 23271 216882 90388284
Sepsis 27.49 12.96 105 23176 179709 90425457
Sepsis syndrome 27.14 12.96 10 23271 963 90604203
Gait inability 27.06 12.96 3 23278 146453 90458713
Weight increased 26.99 12.96 41 23240 417886 90187280
Antidiuretic hormone abnormality 26.76 12.96 5 23276 29 90605137
Boutonneuse fever 26.30 12.96 4 23277 4 90605162
Oesophageal spasm 25.87 12.96 14 23267 3347 90601819
Stenosis 25.86 12.96 12 23269 2072 90603094
Hydronephrosis 25.66 12.96 23 23258 12379 90592787
Shunt infection 25.23 12.96 6 23275 123 90605043
Oesophageal pain 25 12.96 15 23266 4359 90600807
Anterior chamber fibrin 24.91 12.96 6 23275 130 90605036
Acute kidney injury 24.90 12.96 154 23127 320233 90284933
Hypertension 24.90 12.96 50 23231 457482 90147684
Linear IgA disease 24.86 12.96 12 23269 2262 90602904
Staphylococcal sepsis 24.74 12.96 20 23261 9363 90595803
Toxic skin eruption 24.55 12.96 25 23256 15749 90589417
Erythema 24.39 12.96 120 23161 229126 90376040
Macular ischaemia 24.18 12.96 5 23276 52 90605114
Maternal exposure during delivery 24.11 12.96 14 23267 3832 90601334
Hypopyon 24.05 12.96 9 23272 905 90604261
Nephritis allergic 23.98 12.96 7 23274 323 90604843
Echolalia 23.92 12.96 7 23274 326 90604840
Vulval cancer metastatic 23.79 12.96 4 23277 11 90605155
Nail avulsion 23.54 12.96 7 23274 345 90604821
Fanconi syndrome 23.52 12.96 11 23270 1932 90603234
Pyroglutamate increased 23.44 12.96 7 23274 350 90604816
Blood creatinine increased 23.34 12.96 68 23213 101318 90503848
Discomfort 22.91 12.96 22 23259 274313 90330853
Mediastinal effusion 22.68 12.96 5 23276 72 90605094
Cutaneous vasculitis 22.58 12.96 17 23264 7176 90597990
Joint hyperextension 22.57 12.96 7 23274 398 90604768
Irritable bowel syndrome 21.99 12.96 13 23268 207435 90397731
Infection 21.98 12.96 37 23244 362057 90243109
Hepatitis toxic 21.88 12.96 13 23268 3712 90601454
Tachycardia 21.62 12.96 89 23192 157584 90447582
Pyelonephritis 21.56 12.96 27 23254 21289 90583877
Neonatal respiratory distress syndrome 21.35 12.96 12 23269 3089 90602077
Macular detachment 21.00 12.96 5 23276 103 90605063
Bulimia nervosa 20.93 12.96 7 23274 507 90604659
Hyperleukocytosis 20.70 12.96 8 23273 879 90604287
Night sweats 20.65 12.96 4 23277 128762 90476404
Nosocomial infection 20.62 12.96 10 23271 1903 90603263
Insomnia 20.30 12.96 34 23247 333440 90271726
Cyanosis 20.25 12.96 25 23256 19430 90585736
Peripheral swelling 20.11 12.96 48 23233 413058 90192108
Transaminases increased 20.01 12.96 35 23246 37157 90568009
Colitis ischaemic 20.01 12.96 20 23261 12326 90592840
Delusion of replacement 19.87 12.96 4 23277 36 90605130
Delayed delivery 19.77 12.96 4 23277 37 90605129
Product prescribing error 19.76 12.96 31 23250 30114 90575052
Restlessness 19.72 12.96 34 23247 35686 90569480
Anaphylactoid reaction 19.70 12.96 13 23268 4455 90600711
Pulmonary embolism 19.66 12.96 76 23205 130744 90474422
Merycism 19.63 12.96 6 23275 325 90604841
Eosinophilia 19.62 12.96 30 23251 28503 90576663
Bursitis 19.28 12.96 5 23276 131649 90473517
Coma blister 19.27 12.96 5 23276 148 90605018
Bradycardia 19.07 12.96 56 23225 83791 90521375
Lipoma 19.06 12.96 11 23270 2975 90602191
Vanishing twin syndrome 19.05 12.96 5 23276 155 90605011
Hepatosplenomegaly 18.99 12.96 11 23270 2998 90602168
Sinobronchitis 18.80 12.96 7 23274 694 90604472
Gestational diabetes 18.75 12.96 18 23263 10564 90594602
Corneal infiltrates 18.72 12.96 5 23276 166 90605000
Pathogen resistance 18.70 12.96 16 23265 8099 90597067
Eosinophilic pneumonia acute 18.67 12.96 7 23274 708 90604458
Deafness bilateral 18.61 12.96 9 23272 1704 90603462
Listeriosis 18.46 12.96 9 23272 1734 90603432
Retroplacental haematoma 18.44 12.96 5 23276 176 90604990
Idiopathic angioedema 18.25 12.96 4 23277 56 90605110
Lymphoedema 18.21 12.96 20 23261 13733 90591433
Exophthalmos 18.17 12.96 9 23272 1793 90603373
Impaired healing 18.17 12.96 20 23261 234179 90370987
Foreign body sensation in eyes 18.04 12.96 11 23270 3289 90601877
White matter lesion 18.02 12.96 10 23271 2511 90602655
Road traffic accident 18.00 12.96 3 23278 107623 90497543
Pulmonary fibrosis 17.97 12.96 3 23278 107500 90497666
Hallucination 17.92 12.96 47 23234 65912 90539254
Nasal herpes 17.69 12.96 7 23274 819 90604347
Paralysis 17.52 12.96 18 23263 11460 90593706
Retinal infarction 17.47 12.96 4 23277 69 90605097
Blister infected 17.01 12.96 7 23274 906 90604260
Congenital lymphoedema 16.98 12.96 3 23278 12 90605154
Pupillary block 16.98 12.96 3 23278 12 90605154
Defaecation disorder 16.89 12.96 7 23274 922 90604244
Tendon pain 16.76 12.96 11 23270 3737 90601429
Gastrointestinal disorder 16.73 12.96 25 23256 256662 90348504
Respiratory acidosis 16.68 12.96 15 23266 8104 90597062
Throat clearing 16.50 12.96 11 23270 3836 90601330
Intraocular pressure increased 16.37 12.96 14 23267 7079 90598087
Agranulocytosis 16.37 12.96 31 23250 34971 90570195
Symptom recurrence 16.21 12.96 11 23270 3948 90601218
Adverse event 16.19 12.96 5 23276 117413 90487753
Pneumonia klebsiella 16.19 12.96 10 23271 3062 90602104
Acute psychosis 16.17 12.96 10 23271 3068 90602098
Amnesia 16.12 12.96 4 23277 108501 90496665
Nicotine dependence 16.06 12.96 7 23274 1043 90604123
Adverse drug reaction 16.04 12.96 5 23276 116696 90488470
Dermatitis allergic 16.04 12.96 21 23260 17306 90587860
Cerebral mass effect 15.96 12.96 7 23274 1059 90604107
Product preparation issue 15.94 12.96 9 23272 2337 90602829
Serous retinal detachment 15.80 12.96 6 23275 628 90604538
Coagulation time prolonged 15.75 12.96 8 23273 1682 90603484
Natural killer cell count decreased 15.73 12.96 4 23277 109 90605057
Hypersensitivity vasculitis 15.72 12.96 11 23270 4148 90601018
Prescribed overdose 15.72 12.96 3 23278 97622 90507544
Product use issue 15.53 12.96 39 23242 329880 90275286
Gait disturbance 15.45 12.96 27 23254 260469 90344697
Normal newborn 15.27 12.96 24 23257 23338 90581828
B-lymphocyte count increased 15.27 12.96 4 23277 123 90605043
PCO2 abnormal 15.21 12.96 4 23277 125 90605041
Plagiocephaly 15.15 12.96 4 23277 127 90605039
Eye inflammation 15.15 12.96 14 23267 7837 90597329
Somatic symptom disorder 15.15 12.96 10 23271 3431 90601735
Herpes zoster 15.05 12.96 3 23278 94641 90510525
Lung disorder 15.04 12.96 10 23271 149873 90455293
Urticaria contact 15.00 12.96 3 23278 26 90605140
Hypokalaemia 14.92 12.96 70 23211 131046 90474120
Abortion late 14.91 12.96 4 23277 135 90605031
Dermatitis exfoliative generalised 14.91 12.96 12 23269 5581 90599585
Spinal muscular atrophy 14.90 12.96 3 23278 27 90605139
Retinal disorder 14.79 12.96 8 23273 1911 90603255
Vitreous disorder 14.72 12.96 4 23277 142 90605024
Lip oedema 14.64 12.96 11 23270 4628 90600538
Atrial septal defect 14.58 12.96 14 23267 8220 90596946
Injection site reaction 14.47 12.96 3 23278 92077 90513089
Sputum purulent 14.37 12.96 7 23274 1345 90603821
Disturbance in attention 14.28 12.96 35 23246 47074 90558092
Cogwheel rigidity 14.11 12.96 8 23273 2094 90603072
Shock 14.10 12.96 26 23255 28752 90576414
Off label use 13.98 12.96 376 22905 1101876 89503290
Chills 13.96 12.96 69 23212 131912 90473254
Intentional product misuse 13.91 12.96 3 23278 89601 90515565
Abdominal pain 13.85 12.96 159 23122 395562 90209604
Tubulointerstitial nephritis 13.83 12.96 24 23257 25319 90579847
Paranasal sinus discomfort 13.81 12.96 12 23269 6198 90598968
HER2 positive breast cancer 13.74 12.96 5 23276 465 90604701
Megacolon 13.72 12.96 8 23273 2206 90602960
Foramen magnum stenosis 13.70 12.96 4 23277 185 90604981
Proteus infection 13.57 12.96 7 23274 1519 90603647
Corneal epithelium defect 13.53 12.96 5 23276 486 90604680
Erysipelas 13.46 12.96 14 23267 9038 90596128
Enanthema 13.34 12.96 5 23276 505 90604661
Pain in extremity 13.29 12.96 65 23216 450464 90154702
Vitamin A deficiency 13.26 12.96 3 23278 49 90605117
Cholestasis 13.24 12.96 29 23252 36270 90568896
Brain compression 13.11 12.96 5 23276 530 90604636
Junctional ectopic tachycardia 13.08 12.96 4 23277 217 90604949
Fibrin D dimer increased 13.06 12.96 11 23270 5449 90599717
Tendon disorder 13.03 12.96 12 23269 6688 90598478
Immune-mediated renal disorder 12.99 12.96 4 23277 222 90604944
Cytomegalovirus infection 12.99 12.96 24 23257 26578 90578588

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary vasculitis 314.61 15.28 117 20351 6149 42594718
Neuritis 264.90 15.28 103 20365 6117 42594750
Eosinophilic granulomatosis with polyangiitis 235.45 15.28 104 20364 8534 42592333
Respiratory symptom 222.47 15.28 108 20360 10998 42589869
Total lung capacity abnormal 219.50 15.28 82 20386 4361 42596506
Neurological symptom 211.76 15.28 101 20367 9890 42590977
Pulmonary alveolar haemorrhage 190.40 15.28 107 20361 14709 42586158
Vasculitis 184.12 15.28 113 20355 18281 42582586
Spirometry abnormal 180.15 15.28 74 20394 5072 42595795
Conjunctivitis allergic 167 15.28 73 20395 5838 42595029
Forced expiratory volume decreased 158.24 15.28 76 20392 7554 42593313
Normochromic normocytic anaemia 157.67 15.28 80 20388 8951 42591916
Haemoptysis 155.53 15.28 148 20320 46019 42554848
Mite allergy 154.62 15.28 66 20402 4980 42595887
Mycotic allergy 153.28 15.28 65 20403 4826 42596041
Obstructive airways disorder 151.33 15.28 112 20356 24647 42576220
Dust allergy 151.12 15.28 66 20402 5266 42595601
Sleep disorder due to a general medical condition 149.10 15.28 97 20371 17356 42583511
Pulmonary fibrosis 143.87 15.28 112 20356 26569 42574298
Antineutrophil cytoplasmic antibody positive 143.43 15.28 60 20408 4305 42596562
Type IV hypersensitivity reaction 131.49 15.28 48 20420 2389 42598478
Anaphylactic shock 127.40 15.28 99 20369 23418 42577449
Anaphylactic reaction 125.26 15.28 127 20341 42616 42558251
Hypothyroidism 121.84 15.28 110 20358 31974 42568893
Wheezing 117.34 15.28 138 20330 54643 42546224
Full blood count abnormal 110.64 15.28 101 20367 29775 42571092
Arteriosclerosis coronary artery 108.56 15.28 82 20386 18595 42582272
Lung consolidation 107.44 15.28 56 20412 6621 42594246
Nodule 102.98 15.28 68 20400 12466 42588401
Productive cough 100.76 15.28 124 20344 51443 42549424
Asthma 98.58 15.28 135 20333 62179 42538688
Lung disorder 98.12 15.28 118 20350 47805 42553062
Retinal toxicity 90.09 15.28 25 20443 502 42600365
Soft tissue mass 86.01 15.28 28 20440 984 42599883
Multimorbidity 84.02 15.28 27 20441 910 42599957
Retinal infarction 78.92 15.28 17 20451 109 42600758
Arteriosclerosis 76.92 15.28 66 20402 17923 42582944
Oesophageal perforation 76.75 15.28 27 20441 1206 42599661
Macular detachment 72.81 15.28 16 20452 114 42600753
Therapeutic product effect incomplete 71.77 15.28 125 20343 70814 42530053
Capillaritis 71.10 15.28 30 20438 2198 42598669
Toxic epidermal necrolysis 70.27 15.28 75 20393 26675 42574192
Rash maculo-papular 68.15 15.28 87 20381 37416 42563451
Drug reaction with eosinophilia and systemic symptoms 67.79 15.28 92 20376 41983 42558884
Spinal muscular atrophy 67.75 15.28 19 20449 397 42600470
Loss of personal independence in daily activities 67.10 15.28 100 20368 49716 42551151
Macular oedema 66.34 15.28 33 20435 3536 42597331
Resuscitation 63.03 15.28 26 20442 1799 42599068
Superinfection 59.98 15.28 29 20439 2922 42597945
Hypoxia 58.01 15.28 113 20355 69673 42531194
Ocular toxicity 55.68 15.28 16 20452 366 42600501
Pyrexia 52.64 15.28 346 20122 393696 42207171
Endophthalmitis 51.52 15.28 30 20438 4403 42596464
Inflammatory marker increased 51.51 15.28 35 20433 6721 42594146
Transplant failure 51.36 15.28 29 20439 4015 42596852
Pneumococcal sepsis 51.17 15.28 21 20447 1434 42599433
Retinal detachment 50.22 15.28 34 20434 6491 42594376
Stoma closure 49.86 15.28 14 20454 294 42600573
Corneal oedema 46.60 15.28 20 20448 1528 42599339
Bronchospasm 46.58 15.28 43 20425 12842 42588025
Dyspnoea 42.24 15.28 359 20109 442262 42158605
Motor neurone disease 41.63 15.28 14 20454 545 42600322
Anxiety 41.27 15.28 138 20330 118422 42482445
Rales 41.12 15.28 38 20430 11362 42589505
Retinal oedema 41.09 15.28 16 20452 952 42599915
Intestinal intraepithelial lymphocytes increased 40.26 15.28 11 20457 208 42600659
Foetal exposure during pregnancy 39.78 15.28 77 20391 47234 42553633
Kounis syndrome 39.69 15.28 23 20445 3345 42597522
Anticoagulation drug level above therapeutic 39.61 15.28 21 20447 2569 42598298
Lymphadenectomy 39.08 15.28 13 20455 489 42600378
Increased bronchial secretion 38.67 15.28 20 20448 2326 42598541
Bronchial disorder 38.62 15.28 17 20451 1381 42599486
Cryptitis 37.17 15.28 11 20457 280 42600587
Lack of spontaneous speech 37.04 15.28 8 20460 52 42600815
Clostridium difficile colitis 36.56 15.28 48 20420 21204 42579663
Ischaemic cerebral infarction 35.99 15.28 17 20451 1626 42599241
Tachypnoea 35.84 15.28 48 20420 21614 42579253
Product dose omission issue 35.25 15.28 15 20453 154350 42446517
Death 35.13 15.28 113 20355 471072 42129795
Haemorrhagic occlusive retinal vasculitis 34.77 15.28 6 20462 8 42600859
Microvillous inclusion disease 34.63 15.28 10 20458 233 42600634
Oesophageal carcinoma 34.36 15.28 32 20436 9664 42591203
Fatigue 34.22 15.28 102 20366 435539 42165328
Renal graft infection 33.99 15.28 11 20457 379 42600488
Drug abuse 33.82 15.28 5 20463 104766 42496101
Lower respiratory tract infection bacterial 33.77 15.28 12 20456 552 42600315
Respiratory tract infection bacterial 33.57 15.28 17 20451 1892 42598975
Renal injury 33.25 15.28 35 20433 12245 42588622
Sputum increased 33.08 15.28 20 20448 3143 42597724
Maculopathy 32.72 15.28 14 20454 1061 42599806
Congenital pneumonia 32.59 15.28 8 20460 97 42600770
Thrombosis 32.55 15.28 89 20379 68422 42532445
Immunosuppressant drug level increased 32.30 15.28 28 20440 7703 42593164
Metabolic disorder 32.28 15.28 23 20445 4765 42596102
Injury 31.76 15.28 46 20422 22270 42578597
Pathogen resistance 31.65 15.28 33 20435 11417 42589450
Clostridium difficile infection 31.22 15.28 46 20422 22613 42578254
Chest X-ray abnormal 31.19 15.28 22 20446 4486 42596381
Disease complication 31.05 15.28 19 20449 3051 42597816
Platelet count decreased 30.79 15.28 14 20454 138567 42462300
Apoptosis 29.48 15.28 11 20457 582 42600285
Nervous system neoplasm 29.34 15.28 8 20460 150 42600717
Probiotic therapy 29.10 15.28 8 20460 155 42600712
Weight increased 28.95 15.28 8 20460 107975 42492892
Condition aggravated 28.30 15.28 218 20250 260536 42340331
Escherichia infection 28.25 15.28 31 20437 11365 42589502
Quadriparesis 27.56 15.28 16 20452 2334 42598533
Arthralgia 27.42 15.28 35 20433 205203 42395664
Biopsy 27.23 15.28 9 20459 332 42600535
Disease progression 26.87 15.28 18 20450 143638 42457229
Small for dates baby 26.00 15.28 21 20447 5242 42595625
Myocardial ischaemia 25.84 15.28 37 20431 17725 42583142
Confusional state 25.18 15.28 26 20442 167571 42433296
Insomnia 24.67 15.28 13 20455 118240 42482627
Febrile neutropenia 24.46 15.28 32 20436 185671 42415196
Acute generalised exanthematous pustulosis 24.17 15.28 25 20443 8570 42592297
Intestinal ischaemia 24.08 15.28 26 20442 9362 42591505
Fear 24.07 15.28 28 20440 10937 42589930
Malignant neoplasm progression 24.00 15.28 11 20457 108389 42492478
Oral mucosa erosion 23.06 15.28 11 20457 1075 42599792
Atheroembolism 23.01 15.28 8 20460 345 42600522
Brain injury 22.86 15.28 23 20445 7632 42593235
Retinopathy 22.77 15.28 14 20454 2267 42598600
Motor dysfunction 21.66 15.28 23 20445 8123 42592744
Seizure 21.36 15.28 16 20452 120545 42480322
Osteitis 21.05 15.28 12 20456 1692 42599175
Inappropriate schedule of product administration 20.81 15.28 10 20458 95892 42504975
Fibrinolysis increased 20.79 15.28 4 20464 13 42600854
Acute pulmonary oedema 20.52 15.28 23 20445 8628 42592239
Visual acuity reduced 20.49 15.28 33 20435 17517 42583350
Pancytopenia 20.39 15.28 16 20452 117727 42483140
Cardiomegaly 20.22 15.28 32 20436 16734 42584133
Rotavirus infection 19.96 15.28 8 20460 514 42600353
Fluid intake reduced 19.73 15.28 16 20452 4016 42596851
Pneumococcal infection 19.50 15.28 8 20460 546 42600321
Circulatory collapse 19.28 15.28 38 20430 23598 42577269
Inflammation 19.18 15.28 47 20421 33800 42567067
Bronchopneumopathy 18.89 15.28 8 20460 591 42600276
Scoliosis 18.76 15.28 14 20454 3112 42597755
Escherichia urinary tract infection 18.63 15.28 16 20452 4347 42596520
COVID-19 18.55 15.28 17 20451 115931 42484936
Haemoglobin decreased 18.30 15.28 22 20446 132449 42468418
Lymphangitis 18.24 15.28 8 20460 644 42600223
Atelectasis 18.11 15.28 33 20435 19328 42581539
Injection site pain 18.10 15.28 3 20465 57795 42543072
Systemic infection 18.10 15.28 17 20451 5188 42595679
Erosive duodenitis 17.91 15.28 11 20457 1778 42599089
Sleep disorder 17.62 15.28 57 20411 48038 42552829
Nosocomial infection 17.43 15.28 10 20458 1426 42599441
Genitourinary tract infection 17.37 15.28 5 20463 115 42600752
Headache 17.36 15.28 58 20410 239311 42361556
Blindness 17.27 15.28 31 20437 17947 42582920
Demyelination 17.26 15.28 14 20454 3515 42597352
Feeling abnormal 17.21 15.28 6 20462 69780 42531087
Retinal injury 17.17 15.28 5 20463 120 42600747
Septic pulmonary embolism 16.61 15.28 5 20463 135 42600732
Joint swelling 16.52 15.28 6 20462 68016 42532851
Labelled drug-drug interaction medication error 16.44 15.28 28 20440 15554 42585313
Pyramidal tract syndrome 16.40 15.28 6 20462 300 42600567
Conjunctival hyperaemia 16.39 15.28 13 20455 3163 42597704
Premature baby 16.27 15.28 35 20433 23118 42577749
Mastocytosis 16.26 15.28 4 20464 49 42600818
Nausea 16.13 15.28 118 20350 396681 42204186
Abdominal discomfort 16.10 15.28 8 20460 75247 42525620
Epistaxis 16.05 15.28 6 20462 66820 42534047
Pain 15.98 15.28 62 20406 244786 42356081
Talipes 15.67 15.28 11 20457 2225 42598642
Cerebral ischaemia 15.66 15.28 18 20450 6941 42593926
Intentional overdose 15.40 15.28 3 20465 51453 42549414
Patent ductus arteriosus 15.36 15.28 13 20455 3463 42597404
Blood pressure decreased 15.30 15.28 62 20406 58270 42542597

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 361.52 12.88 311 39293 113989 110435706
Anaphylactic shock 354.11 12.88 224 39380 51322 110498373
Pulmonary vasculitis 346.68 12.88 118 39486 6442 110543253
Neuritis 280.45 12.88 104 39500 7295 110542400
Eosinophilic granulomatosis with polyangiitis 250.03 12.88 106 39498 10580 110539115
Total lung capacity abnormal 244.37 12.88 83 39521 4500 110545195
Respiratory symptom 225.00 12.88 109 39495 14836 110534859
Type IV hypersensitivity reaction 218.42 12.88 82 39522 5951 110543744
Macular oedema 213.98 12.88 84 39520 6882 110542813
Spirometry abnormal 200.05 12.88 75 39529 5422 110544273
Neurological symptom 199.92 12.88 102 39502 15506 110534189
Retinal detachment 197.97 12.88 91 39513 11009 110538686
Pulmonary alveolar haemorrhage 197.01 12.88 110 39494 20040 110529655
Angioedema 191.41 12.88 205 39399 98295 110451400
Conjunctivitis allergic 179.77 12.88 74 39530 6857 110542838
Drug reaction with eosinophilia and systemic symptoms 170.42 12.88 177 39427 81918 110467777
Mite allergy 167.84 12.88 67 39537 5736 110543959
Dust allergy 165.66 12.88 67 39537 5934 110543761
Vasculitis 163.36 12.88 121 39483 35752 110513943
Mycotic allergy 162.73 12.88 66 39538 5888 110543807
Antineutrophil cytoplasmic antibody positive 155.17 12.88 61 39543 5015 110544680
Normochromic normocytic anaemia 154.76 12.88 81 39523 12976 110536719
Swollen tongue 152.78 12.88 145 39459 60217 110489478
Haemoptysis 151.99 12.88 156 39448 71198 110478497
Retinal toxicity 150.35 12.88 45 39559 1614 110548081
Corneal oedema 147.99 12.88 52 39552 3121 110546574
Forced expiratory volume decreased 145.59 12.88 78 39526 13098 110536597
Obstructive airways disorder 144.59 12.88 125 39479 46024 110503671
Swelling face 135.15 12.88 166 39438 92155 110457540
Bronchospasm 131.00 12.88 99 39505 30140 110519555
Rash maculo-papular 129.46 12.88 146 39458 74076 110475619
Arteriosclerosis coronary artery 119.49 12.88 87 39517 25031 110524664
Retinal oedema 113.05 12.88 36 39568 1591 110548104
Hypothyroidism 111.43 12.88 134 39470 72765 110476930
Dysphonia 110.27 12.88 136 39468 75793 110473902
Retinal infarction 108.17 12.88 23 39581 192 110549503
Ocular toxicity 107.16 12.88 33 39571 1305 110548390
Endophthalmitis 106.29 12.88 54 39550 8133 110541562
Drug ineffective for unapproved indication 106.21 12.88 156 39448 102682 110447013
Joint swelling 106.15 12.88 16 39588 442829 110106866
Lung consolidation 101.88 12.88 57 39547 10419 110539276
Resuscitation 99.43 12.88 38 39566 2895 110546800
Full blood count abnormal 99.00 12.88 111 39493 55941 110493754
Macular detachment 93.21 12.88 21 39583 235 110549460
Infusion related reaction 93.13 12.88 13 39591 381149 110168546
Corneal opacity 92.40 12.88 29 39575 1222 110548473
Clostridium difficile infection 88.27 12.88 101 39503 52028 110497667
Anterior chamber inflammation 87.80 12.88 25 39579 750 110548945
Sleep disorder due to a general medical condition 83.27 12.88 98 39506 52014 110497681
Arteriosclerosis 79.42 12.88 68 39536 24699 110524996
Soft tissue mass 78.74 12.88 27 39577 1506 110548189
Productive cough 78.20 12.88 144 39460 114161 110435534
Capillaritis 76.98 12.88 30 39574 2409 110547286
Type I hypersensitivity 76.73 12.88 40 39564 6353 110543342
Kounis syndrome 76.68 12.88 39 39565 5886 110543809
Toxic epidermal necrolysis 76.61 12.88 98 39506 56629 110493066
Rheumatoid arthritis 76.11 12.88 9 39595 299604 110250091
Multimorbidity 75.08 12.88 26 39578 1494 110548201
Arthropathy 74.64 12.88 8 39596 287514 110262181
Clostridium difficile colitis 74.42 12.88 85 39519 43693 110506002
Circulatory collapse 73.98 12.88 84 39520 42909 110506786
Completed suicide 73.80 12.88 3 39601 242378 110307317
Visual acuity reduced 73.34 12.88 73 39531 32100 110517595
Oesophageal perforation 72.85 12.88 26 39578 1633 110548062
Systemic lupus erythematosus 71.67 12.88 5 39599 254333 110295362
Tachypnoea 69.54 12.88 78 39526 39317 110510378
Pseudomembranous colitis 68.27 12.88 37 39567 6354 110543341
Spinal muscular atrophy 67.99 12.88 18 39586 409 110549286
Nodule 67.04 12.88 70 39534 32561 110517134
Alopecia 66.11 12.88 24 39580 364729 110184966
Musculoskeletal stiffness 65.01 12.88 11 39593 279811 110269884
Weight increased 64.45 12.88 35 39569 419609 110130086
Glossodynia 63.62 12.88 4 39600 222000 110327695
Stoma closure 63.48 12.88 17 39587 404 110549291
Hypoxia 63.38 12.88 142 39462 129373 110420322
Cystoid macular oedema 62.93 12.88 27 39577 2773 110546922
Pericarditis 62.63 12.88 4 39600 219110 110330585
Fatigue 62.46 12.88 225 39379 1215733 109333962
Treatment failure 57.95 12.88 14 39590 277220 110272475
Pain 57.87 12.88 164 39440 954791 109594904
Arthralgia 56.51 12.88 122 39482 779510 109770185
Pneumococcal sepsis 55.27 12.88 23 39581 2189 110547506
Abdominal discomfort 53.35 12.88 38 39566 393820 110155875
Corneal deposits 53.29 12.88 16 39588 580 110549115
Pulmonary fibrosis 52.32 12.88 114 39490 101928 110447767
Pathogen resistance 51.59 12.88 46 39558 17626 110532069
Maculopathy 51.43 12.88 24 39580 3003 110546692
Cross sensitivity reaction 50.65 12.88 29 39575 5538 110544157
Therapeutic product effect decreased 49.78 12.88 13 39591 244303 110305392
Dysbiosis 49.37 12.88 21 39583 2111 110547584
Folliculitis 48.09 12.88 3 39601 167650 110382045
Transplant failure 47.67 12.88 28 39576 5607 110544088
Pyrexia 47.63 12.88 511 39093 897754 109651941
Renal injury 47.42 12.88 45 39559 18668 110531027
Psoriatic arthropathy 47.35 12.88 7 39597 196754 110352941
Superinfection 47.09 12.88 28 39576 5735 110543960
Accidental overdose 46.94 12.88 74 39530 51760 110497935
Pyroglutamic acidosis 46.67 12.88 20 39584 2048 110547647
Blood cholesterol increased 45.82 12.88 6 39598 184779 110364916
Wound 44.94 12.88 14 39590 234423 110315272
Insomnia 44.76 12.88 38 39566 360552 110189143
Premature delivery 44.66 12.88 55 39549 30577 110519118
Contraindicated product administered 43.85 12.88 17 39587 248250 110301445
Intentional product use issue 43.75 12.88 17 39587 247889 110301806
Type 2 diabetes mellitus 43.36 12.88 6 39598 177226 110372469
Hypersensitivity 43.33 12.88 270 39334 403728 110145967
Blood pressure decreased 43.26 12.88 114 39490 114977 110434718
Multiple organ dysfunction syndrome 43.21 12.88 136 39468 151574 110398121
Exposure during pregnancy 43.10 12.88 145 39459 167279 110382416
Intestinal intraepithelial lymphocytes increased 42.32 12.88 11 39593 232 110549463
Motor neurone disease 42.11 12.88 14 39590 710 110548985
Premature rupture of membranes 41.77 12.88 24 39580 4613 110545082
Nasopharyngitis 41.54 12.88 48 39556 394313 110155382
Inflammatory marker increased 40.93 12.88 37 39567 14432 110535263
Haemorrhagic occlusive retinal vasculitis 40.60 12.88 9 39595 93 110549602
Cataract operation complication 40.58 12.88 11 39593 274 110549421
Rales 40.31 12.88 47 39557 24692 110525003
Pneumonia mycoplasmal 39.82 12.88 17 39587 1724 110547971
Anticoagulation drug level above therapeutic 39.15 12.88 23 39581 4607 110545088
Irritable bowel syndrome 39.15 12.88 6 39598 164209 110385486
Nosocomial infection 38.35 12.88 20 39584 3179 110546516
Pulmonary embolism 38.07 12.88 165 39439 214309 110335386
Vaccination site pain 37.75 12.88 12 39592 527 110549168
Fall 37.70 12.88 102 39502 603380 109946315
Thrombosis 37.20 12.88 104 39500 108558 110441137
Cryptitis 37.09 12.88 11 39593 382 110549313
Ill-defined disorder 36.78 12.88 6 39598 156847 110392848
Hypertension 36.75 12.88 80 39524 510004 110039691
Microvillous inclusion disease 36.16 12.88 10 39594 269 110549426
Pericoronitis 36.08 12.88 9 39595 160 110549535
Myocardial ischaemia 35.86 12.88 46 39558 26638 110523057
Oesophageal carcinoma 35.65 12.88 31 39573 11493 110538202
Airway peak pressure increased 35.64 12.88 12 39592 633 110549062
Probiotic therapy 35.57 12.88 9 39595 170 110549525
Bronchial disorder 35.13 12.88 18 39586 2758 110546937
Respiratory tract infection bacterial 34.49 12.88 17 39587 2399 110547296
Increased bronchial secretion 34.41 12.88 20 39584 3928 110545767
Ischaemic cerebral infarction 34.13 12.88 18 39586 2927 110546768
Delivery 34.04 12.88 13 39591 988 110548707
Dyspnoea 33.82 12.88 570 39034 1106302 109443393
Parophthalmia 33.73 12.88 11 39593 525 110549170
Face oedema 33.42 12.88 50 39554 33419 110516276
Stevens-Johnson syndrome 33.21 12.88 60 39544 46841 110502854
Cardiac arrest 33.12 12.88 149 39455 196604 110353091
Lower respiratory tract infection bacterial 33.02 12.88 13 39591 1072 110548623
Bursitis 32.73 12.88 4 39600 129914 110419781
Anterior chamber fibrin 32.58 12.88 9 39595 241 110549454
Swelling 32.55 12.88 47 39557 350994 110198701
Gait inability 32.47 12.88 5 39599 136371 110413324
Escherichia infection 31.92 12.88 41 39563 23775 110525920
Lymphadenectomy 31.87 12.88 14 39590 1522 110548173
Retinal disorder 31.84 12.88 16 39588 2354 110547341
Acute generalised exanthematous pustulosis 31.75 12.88 39 39565 21625 110528070
Fibrinolysis increased 31.58 12.88 6 39598 26 110549669
Drug abuse 31.57 12.88 12 39592 177399 110372296
Fear 31.20 12.88 40 39564 23153 110526542
Peripheral swelling 31.09 12.88 61 39543 403973 110145722
Hepatic enzyme increased 30.71 12.88 42 39562 320850 110228845
Anxiety 30.58 12.88 220 39384 344858 110204837
Apoptosis 30.46 12.88 11 39593 715 110548980
Gait disturbance 30.22 12.88 33 39571 278175 110271520
Shock 29.92 12.88 62 39542 53526 110496169
Retinopathy 29.77 12.88 19 39585 4410 110545285
Renal graft infection 29.70 12.88 11 39593 768 110548927
Brain injury 29.65 12.88 30 39574 13446 110536249
Drug interaction 29.49 12.88 291 39313 499892 110049803
Immunosuppressant drug level increased 29.34 12.88 28 39576 11696 110537999
Trimethylaminuria 29.23 12.88 8 39596 207 110549488
Sepsis 29.18 12.88 209 39395 327137 110222558
Chest X-ray abnormal 28.64 12.88 24 39580 8463 110541232
Asthma 28.53 12.88 170 39434 250121 110299574
Intestinal ischaemia 28.49 12.88 32 39572 16147 110533548
Musculoskeletal pain 28.46 12.88 15 39589 183008 110366687
Erythema 28.29 12.88 190 39414 291257 110258438
Memory impairment 27.98 12.88 18 39586 196926 110352769
Sputum increased 27.53 12.88 20 39584 5731 110543964
Lack of spontaneous speech 27.39 12.88 8 39596 263 110549432
Cutaneous vasculitis 27.39 12.88 28 39576 12701 110536994
Intraocular pressure increased 27.26 12.88 26 39578 10850 110538845
Confusional state 27.20 12.88 82 39522 468598 110081097
Cardiac massage 27.05 12.88 5 39599 18 110549677
Renal failure 25.89 12.88 154 39450 226420 110323275
Death 25.19 12.88 147 39457 698722 109850973
Boutonneuse fever 24.97 12.88 4 39600 4 110549691
Oliguria 24.82 12.88 32 39572 18625 110531070
Atheroembolism 24.71 12.88 8 39596 373 110549322
Toxic skin eruption 24.52 12.88 39 39565 27476 110522219
Cardiovascular insufficiency 24.35 12.88 15 39589 3273 110546422
Metabolic disorder 24.23 12.88 24 39580 10486 110539209
Transaminases increased 24.03 12.88 63 39541 63327 110486368
Quadriparesis 23.98 12.88 17 39587 4690 110545005
Discomfort 23.84 12.88 25 39579 214682 110335013
Fibromyalgia 23.77 12.88 16 39588 170893 110378802
Meningitis candida 23.74 12.88 7 39597 238 110549457
Vulval cancer metastatic 23.70 12.88 4 39600 7 110549688
Dry mouth 23.67 12.88 22 39582 199926 110349769
Intentional product misuse 23.63 12.88 9 39595 132895 110416800
Lung disorder 23.62 12.88 127 39477 179920 110369775
Escherichia urinary tract infection 23.53 12.88 29 39575 16133 110533562
Clostridium test positive 23.51 12.88 24 39580 10869 110538826
Road traffic accident 23.27 12.88 5 39599 107393 110442302
Eye inflammation 23.13 12.88 22 39582 9149 110540546
Anhedonia 22.97 12.88 28 39576 15400 110534295
Biopsy 22.97 12.88 9 39595 733 110548962
Disease complication 22.88 12.88 18 39586 5809 110543886
Conjunctival hyperaemia 22.87 12.88 18 39586 5813 110543882
Tachycardia 22.74 12.88 149 39455 226496 110323199
Sinusitis 22.64 12.88 45 39559 296643 110253052
Dyspepsia 22.62 12.88 21 39583 190944 110358751
Venous thrombosis 22.60 12.88 21 39583 8484 110541211
Loss of personal independence in daily activities 22.59 12.88 110 39494 149910 110399785
Hypercholesterolaemia 22.39 12.88 3 39601 90834 110458861
Eosinophilia 22.39 12.88 58 39546 57878 110491817
Hypersensitivity vasculitis 22.14 12.88 19 39585 6918 110542777
Infection 22.00 12.88 62 39542 362138 110187557
Bulimia nervosa 21.90 12.88 7 39597 313 110549382
Gastrointestinal disorder 21.83 12.88 33 39571 241919 110307776
Injection site reaction 21.82 12.88 3 39601 89067 110460628
Serous retinal detachment 21.62 12.88 11 39593 1661 110548034
Labelled drug-drug interaction medication error 21.40 12.88 38 39566 29264 110520431
Serratia infection 21.17 12.88 12 39592 2247 110547448
Metabolic acidosis 21.06 12.88 81 39523 99663 110450032
Neck pain 20.81 12.88 9 39595 123121 110426574
Maternal exposure during delivery 20.81 12.88 14 39590 3551 110546144
Amnesia 20.73 12.88 6 39598 105402 110444293
Mediastinal effusion 20.72 12.88 5 39599 77 110549618
Joint hyperextension 20.70 12.88 7 39597 374 110549321
Pneumonia 20.66 12.88 434 39170 876280 109673415
Antidiuretic hormone abnormality 20.66 12.88 5 39599 78 110549617
Hypotension 20.66 12.88 282 39322 523567 110026128
Sciatica 20.65 12.88 4 39600 92395 110457300
Stomatitis 20.61 12.88 41 39563 270201 110279494
Therapeutic product effect incomplete 20.57 12.88 144 39460 223661 110326034
Vitreous disorder 20.52 12.88 7 39597 384 110549311
Oesophageal spasm 20.45 12.88 14 39590 3652 110546043
Nausea 20.31 12.88 316 39288 1235374 109314321
Blindness 20.22 12.88 42 39562 36317 110513378
Delayed delivery 20.11 12.88 4 39600 23 110549672
Product use issue 19.95 12.88 52 39552 311643 110238052
Blood pressure increased 19.87 12.88 39 39565 258334 110291361
Nephritis allergic 19.72 12.88 9 39595 1070 110548625
Toxoplasmosis 19.58 12.88 13 39591 3226 110546469
Paralysis 19.57 12.88 26 39578 15574 110534121
Osteoarthritis 19.46 12.88 22 39582 182601 110367094
Conjunctival oedema 19.43 12.88 10 39594 1546 110548149
Sepsis syndrome 19.19 12.88 10 39594 1586 110548109
Vanishing twin syndrome 18.99 12.88 5 39599 111 110549584
Mobility decreased 18.99 12.88 35 39569 237387 110312308
Product dose omission issue 18.87 12.88 56 39548 321726 110227969
Wheezing 18.85 12.88 156 39448 255074 110294621
Lip swelling 18.84 12.88 50 39554 50617 110499078
Retinal haemorrhage 18.83 12.88 20 39584 9481 110540214
Neuropathy peripheral 18.66 12.88 22 39582 179255 110370440
Shunt infection 18.55 12.88 6 39598 279 110549416
Ascites 18.49 12.88 74 39530 92734 110456961
Exophthalmos 18.46 12.88 11 39593 2262 110547433
Erosive duodenitis 18.38 12.88 11 39593 2280 110547415
Oesophageal pain 18.35 12.88 15 39589 5110 110544585
Hepatosplenomegaly 18.22 12.88 17 39587 6902 110542793
Hypoaesthesia 18.20 12.88 55 39549 314168 110235527
White blood cell count decreased 18.18 12.88 34 39570 229356 110320339
Echolalia 18.18 12.88 7 39597 544 110549151
Arthritis 18.06 12.88 20 39584 167566 110382129
Hydronephrosis 18.01 12.88 29 39575 20636 110529059
Polyneuropathy 17.83 12.88 37 39567 31975 110517720
Rotavirus infection 17.79 12.88 8 39596 919 110548776
Bronchopneumopathy 17.74 12.88 8 39596 925 110548770
Oral mucosa erosion 17.70 12.88 11 39593 2437 110547258
Impaired healing 17.58 12.88 27 39577 196690 110353005
Platelet count decreased 17.53 12.88 35 39569 230408 110319287
Optic atrophy 17.41 12.88 11 39593 2510 110547185
Lower limb fracture 17.40 12.88 3 39601 75345 110474350
Cyanosis 17.30 12.88 35 39569 29706 110519989
Hypopyon 17.25 12.88 9 39595 1431 110548264
Demyelination 17.20 12.88 19 39585 9410 110540285
Skin test positive 17.20 12.88 9 39595 1440 110548255
Disease progression 16.96 12.88 39 39565 243995 110305700
Pneumonia klebsiella 16.90 12.88 16 39588 6616 110543079
Deafness bilateral 16.70 12.88 11 39593 2693 110547002
Cholestasis 16.70 12.88 56 39548 64462 110485233
Gamma-glutamyltransferase increased 16.57 12.88 54 39550 61255 110488440
Lymphangitis 16.51 12.88 9 39595 1563 110548132
Toxic anterior segment syndrome 16.51 12.88 12 39592 3442 110546253
Drug resistance 16.46 12.88 51 39553 56323 110493372
Cardiopulmonary failure 16.31 12.88 17 39587 7886 110541809
Lower respiratory tract infection 15.98 12.88 40 39564 243066 110306629
Nasal herpes 15.98 12.88 7 39597 756 110548939
Muscle spasms 15.88 12.88 49 39555 278108 110271587
Jaundice 15.85 12.88 52 39552 59184 110490511
Gastrooesophageal reflux disease 15.80 12.88 25 39579 179951 110369744
Coma blister 15.57 12.88 5 39599 227 110549468
Retinal injury 15.50 12.88 6 39598 473 110549222
Cardiomegaly 15.44 12.88 33 39571 29097 110520598
Emotional distress 15.42 12.88 43 39561 44804 110504891
Macular ischaemia 15.38 12.88 5 39599 236 110549459
Leukocytosis 15.08 12.88 48 39556 53780 110495915
Lipoma 15.06 12.88 12 39592 3943 110545752
Bladder neck obstruction 15.02 12.88 4 39600 93 110549602
Acute pulmonary oedema 15.02 12.88 24 39580 16972 110532723
Systemic infection 14.91 12.88 18 39586 9801 110539894
Prosthetic cardiac valve stenosis 14.84 12.88 3 39601 19 110549676
Foreign body sensation in eyes 14.62 12.88 11 39593 3323 110546372
Product monitoring error 14.61 12.88 17 39587 8910 110540785
Adverse drug reaction 14.51 12.88 10 39594 105549 110444146
Pneumonectomy 14.49 12.88 4 39600 107 110549588
Red blood cell sedimentation rate increased 14.43 12.88 5 39599 78297 110471398
Tinnitus 14.32 12.88 51 39553 60489 110489206
Osteitis 14.19 12.88 12 39592 4284 110545411
Genitourinary tract infection 14.12 12.88 5 39599 307 110549388
Endotracheal intubation 14.11 12.88 14 39590 6130 110543565
Fanconi syndrome 14.09 12.88 11 39593 3508 110546187
Blood glucose increased 14.07 12.88 16 39588 132480 110417215
Urticaria contact 14.01 12.88 3 39601 26 110549669
Linear IgA disease 13.97 12.88 12 39592 4377 110545318
Haemorrhoids thrombosed 13.96 12.88 5 39599 317 110549378
Acinetobacter infection 13.95 12.88 11 39593 3562 110546133
Prescribed overdose 13.87 12.88 7 39597 87574 110462121
Amaurosis 13.72 12.88 8 39596 1581 110548114
Septic pulmonary embolism 13.71 12.88 5 39599 334 110549361
Psoriasis 13.71 12.88 18 39586 139975 110409720
Underdose 13.69 12.88 3 39601 63551 110486144
Gestational diabetes 13.67 12.88 15 39589 7374 110542321
Decreased appetite 13.67 12.88 107 39497 475739 110073956
Sedation 13.64 12.88 4 39600 69679 110480016
Acute hepatic failure 13.57 12.88 36 39568 36432 110513263
Urticaria 13.52 12.88 174 39430 318683 110231012
Respiratory failure 13.51 12.88 127 39477 215205 110334490
Natural killer cell count decreased 13.48 12.88 4 39600 139 110549556
Therapeutic response decreased 13.46 12.88 9 39595 96490 110453205
Atelectasis 13.42 12.88 36 39568 36676 110513019
Night sweats 13.36 12.88 17 39587 133966 110415729
Corneal infiltrates 13.34 12.88 5 39599 361 110549334
B-lymphocyte count increased 13.32 12.88 4 39600 145 110549550
Somnolence 13.29 12.88 58 39546 297391 110252304
Inappropriate schedule of product administration 13 12.88 34 39570 203603 110346092
HER2 positive breast cancer 12.99 12.88 5 39599 388 110549307
Joint stiffness 12.91 12.88 4 39600 67239 110482456

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DC02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Second-generation cephalosporins
ATC J01DC52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Second-generation cephalosporins
ATC J01RA03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AA27 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:88188 drug allergen
CHEBI has role CHEBI:35441 antiinfective agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents

Related Drugs by ATC class:

J01DC Second-generation cephalosporins 13 drugs
cefaclorcefamandolecefbuperazonecefmetazolecefminoxcefonicidceforanidecefotetancefotiamcefoxitincefprozilflomoxef show all 13 →
J01RA Combinations of antibacterials 18 drugs
amikacinazithromycincefepimecefiximeciprofloxacinfluconazolelevofloxacinmetronidazolenitazoxanidenorfloxacinnystatinofloxacin show all 18 →
S01AA Antibiotics 27 drugs
amikacinampicillinazidamfenicolazithromycinbacitracinbenzylpenicillincefmenoximechloramphenicolchlortetracyclinedibekacindihydrostreptomycinerythromycin show all 27 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Streptococcal meningitis indication 4510004 DOID:11574
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Staphylococcal meningitis indication 12166008
Gonorrhea indication 15628003 DOID:7551
Haemophilus Influenzae Acute Otitis Media indication 19021002
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Lyme disease indication 23502006 DOID:11729
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Streptococcal tonsillitis indication 41582007
Gonorrhea of rectum indication 42746002
Impetigo indication 48277006 DOID:8504
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute maxillary sinusitis indication 68272006 DOID:2050
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Gonorrhea of pharynx indication 74372003
Acute bacterial sinusitis indication 75498004
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Escherichia coli urinary tract infection indication 301011002
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Moraxella Catarrhalis Acute Otitis Media indication 703469002
Haemophilus Influenzae Bronchitis indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Disseminated Gonococcal Infection indication
Streptococcus Pneumoniae Bronchitis indication
Haemophilus Parainfluenzae Bronchitis indication
Staphylococcus Aureus Joint Infection indication
H. Influenzae Meningitis indication
Prevention of Perioperative Infection indication
Haemophilus Influenzae Chronic Bronchitis indication
Haemophilus Septicemia indication
Haemophilus Parainfluenzae Chronic Bronchitis indication
Open Heart Surgery Infection Prevention indication
Pyrexia of unknown origin off-label use 7520000
Sepsis of the newborn off-label use 206376005
Neonatal pneumonia off-label use 233619008
Neonatal meningitis off-label use 276674008
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.32 acidic
pKa2 13.33 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme IC50 5.92 WOMBAT-PK
72 kDa type IV collagenase Enzyme IC50 4.37 WOMBAT-PK
Matrix metalloproteinase-9 Enzyme IC50 4.96 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4019668 VUID
N0000147760 NUI
D00262 KEGG_DRUG
56238-63-2 SECONDARY_CAS_RN
204144 RXNORM
C0007562 UMLSCUI
CHEBI:3515 CHEBI
KOV PDB_CHEM_ID
CHEMBL2146124 ChEMBL_ID
CHEMBL1436 ChEMBL_ID
D002444 MESH_DESCRIPTOR_UI
DB01112 DRUGBANK_ID
5479529 PUBCHEM_CID
10900 IUPHAR_LIGAND_ID
3902 INN_ID
O1R9FJ93ED UNII
2973 MMSL
4389 MMSL
d00056 MMSL
002731 NDDF
003590 NDDF
372833007 SNOMEDCT_US
48753004 SNOMEDCT_US
73986003 SNOMEDCT_US
4017551 VANDF
4019668 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9567 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 23 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9568 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 23 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9569 INJECTION, POWDER, FOR SOLUTION 7.50 g INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9976 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9977 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 22 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9979 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 22 sections
Cefuroxime and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-3112 INJECTION, SOLUTION 750 mg INTRAVENOUS NDA 24 sections
Cefuroxime and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-3114 INJECTION, SOLUTION 1.50 g INTRAVENOUS NDA 24 sections
Cefuroxime sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-118 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 25 sections
Cefuroxime sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-119 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 44567-712 INJECTION, POWDER, FOR SOLUTION 7.50 g INTRAVENOUS ANDA 25 sections